Ionis Pharmaceuticals

Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Motley Fool
Ionis Pharmaceuticals
Flag link:
Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS
Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS
BioSpace
Biogen
tofersen
antisense
Ionis Pharmaceuticals
ALS
Flag link:
'Pathbreaking' Ionis trial offers way forward in Huntington's disease
'Pathbreaking' Ionis trial offers way forward in Huntington's disease
Biopharma Dive
Ionis Pharmaceuticals
Roche
Huntington's disease6
RG6042
Flag link:
Ionis slides after AveXis reports SMA data for Zolgensma
Ionis slides after AveXis reports SMA data for Zolgensma
BioCentury
Ionis Pharmaceuticals
AveXis
Zolgensma
lcinical trials
spinal muscular atrophy
Flag link:
1 Biotech That Biogen Should Buy ... but Probably Won't
1 Biotech That Biogen Should Buy ... but Probably Won't
Motley Fool
Biogen
Ionis Pharmaceuticals
M&A
Flag link:
Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs
Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs
Motley Fool
Ionis Pharmaceuticals
earnings
Flag link:
Novartis aims to pump up cardio business with Ionis deal
Novartis aims to pump up cardio business with Ionis deal
Yahoo/Reuters
Novartis
Ionis Pharmaceuticals
TQJ230
Flag link:
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Biopharma Dive
R&D
Moderna Therapeutics
Sarepta Therapeutics
Ionis Pharmaceuticals
Flag link:
Biogen opts in for Ionis' ALS candidate, plans pivotal trial
Biogen opts in for Ionis' ALS candidate, plans pivotal trial
BioCentury
BIIB067
Biogen
Ionis Pharmaceuticals
ALS
Flag link:
Ionis, Akcea succeed in heart drug trial, setting up Novartis decision
Ionis, Akcea succeed in heart drug trial, setting up Novartis decision
Biopharma Dive
Akcea Therapeutics
Ionis Pharmaceuticals
clinical trials
Novartis
AKCEA-APO(a)-Lrx
Flag link:
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
type 2 diabetes
antisense
Flag link:
Roche gets option to Ionis' antisense dry AMD candidate
Roche gets option to Ionis' antisense dry AMD candidate
BioCentury
Roche
Ionis Pharmaceuticals
IONIS-FB-LRx
antisense
dry age-related macular degeneration
Flag link:
FDA clears rare disease therapy from Akcea, Ionis
FDA clears rare disease therapy from Akcea, Ionis
Biopharma Dive
FDA
Akcea
Ionis Pharmaceuticals
Tegsedi
Onpattro
Alnylam
hATTR amyloidosis
Flag link:
Ionis, Rockefeller team find peripheral blood target for Alzheimer's
Ionis, Rockefeller team find peripheral blood target for Alzheimer's
BioCentury
Ionis Pharmaceuticals
Rockefeller University
Alzheimer's disease
drug development
Flag link:
Why Biogen's Stock Ripped Higher in July
Why Biogen's Stock Ripped Higher in July
Motley Fool
Biogen
Eisai
BAN2401
Alzheimer's disease
Spinraza
Ionis Pharmaceuticals
Flag link:
Ionis-backed Dynacure bags €47M to start clinical trials
Ionis-backed Dynacure bags €47M to start clinical trials
Fierce Biotech
Dynacure
Ionis Pharmaceuticals
antisense
oligonucleotide
CNM muscular disorders
Flag link:
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Motley Fool
PTC Therapeutics
risdiplam
Biogen
Ionis Pharmaceuticals
spinal muscular atrophy
Sarepta Therapeutics
Translarna
Emflaza
Flag link:
FDA Advisory Committee Votes in Favor of Waylivra for Treatment of Familial Chylomicronemia Syndrome
FDA Advisory Committee Votes in Favor of Waylivra for Treatment of Familial Chylomicronemia Syndrome
CP Wire
Akcea Therapeutics
Ionis Pharmaceuticals
FDA
advisory panel
Waylivra
Volanesorsen
FCS
Flag link:
Outlook for Ionis, Akcea drug marred by safety concerns
Outlook for Ionis, Akcea drug marred by safety concerns
Biopharma Dive
Ionis Pharmaceuticals
Akcea Therapeutics
FDA
advisory panel
Volanesorsen
Flag link:
Biogen To Pay Ionis $1 Billion To Develop Brain Drugs
Biogen To Pay Ionis $1 Billion To Develop Brain Drugs
Forbes
Biogen
Ionis Pharmaceuticals
drug development
R&D
Flag link:

Pages